Fingolimod (Gilenya)

Reanalysis of previous study results show that fingolimod reduced the rate of brain volume loss by about a third compared to Avonex or placebo, that the overall reduction in relapse rate was also demonstrated across subgroups such as gender, age, and disease activity, and that no further safety concerns were identified in a two year extension study. Results presented at the AAN (American Academy of Neurology) meeting. Novartis press release Bloomberg Fingolimod (Gilenya) - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news